Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
Department of Ophthalmology, Shanxi Eye Hospital, Taiyuan City, China.
Ophthalmic Res. 2020;63(6):517-523. doi: 10.1159/000508250. Epub 2020 Apr 28.
Different splicing of vascular endothelial growth factor (VEGF) gene results in 2 families of VEGF, the proangiogenic isoforms (VEGFxxxa) and the antiangiogenic isoforms (VEGFxxxb). VEGF165b is the major antiangiogenic isoform of VEGF and the most studied member of the VEGFxxxb family so far.
To determine the concentration of VEGF165b and VEGF in the aqueous humor (AH) in diabetic eyes with or without diabetic retinopathy (DR) and to address the predictive value of VEGF165b/VEGF ratio for progression of DR.
AH samples from 20 eyes in healthy controls (CON group), 40 eyes in diabetic patients without DR (nDR group), and 30 eyes in diabetic patients with mild nonproliferative DR (DR group) were collected. All of the patients were followed up for at least 5 years. VEGF165b and VEGF levels of AH samples were measured by enzyme-linked immunosorbent assay (ELISA). The predictive value of the initial VEGF165b/VEGF ratio for progression of DR was studied.
The mean concentration of VEGF165b significantly decreased in diabetic eyes vs. controls. The mean concentration of VEGF significantly increased in the DR group vs. the CON group. The VEGF165b/VEGF ratio was significantly lower in diabetic patients compared to the CON group. The VEGF165b/VEGF ratio was significantly lower in diabetic patients compared to the control group. The mean follow-up was 66.1months (range 60-71 months). The risk of DR progression was greater with a lower VEGF165b/VEGF ratio.
The VEGF165b/VEGF ratio is lower in the AH of DR patients and the decreased ratio of VEGF165b/VEGF predicts DR progression.
血管内皮生长因子(VEGF)基因的不同剪接导致了 VEGF 的 2 个家族,即促血管生成的异构体(VEGFxxxa)和抗血管生成的异构体(VEGFxxxb)。VEGF165b 是 VEGF 的主要抗血管生成异构体,也是迄今为止 VEGFxxxb 家族中研究最多的成员。
确定糖尿病眼伴或不伴糖尿病视网膜病变(DR)患者房水中 VEGF165b 和 VEGF 的浓度,并探讨 VEGF165b/VEGF 比值对 DR 进展的预测价值。
收集 20 例正常对照者(CON 组)、40 例无 DR 的糖尿病患者(nDR 组)和 30 例轻度非增生性 DR 患者(DR 组)的房水样本。所有患者均随访至少 5 年。采用酶联免疫吸附试验(ELISA)检测房水样本中 VEGF165b 和 VEGF 的浓度。研究初始 VEGF165b/VEGF 比值对 DR 进展的预测价值。
与对照组相比,糖尿病眼房水中 VEGF165b 的平均浓度显著降低。DR 组 VEGF 的平均浓度显著高于 CON 组。与 CON 组相比,糖尿病患者的 VEGF165b/VEGF 比值明显较低。与对照组相比,糖尿病患者的 VEGF165b/VEGF 比值明显较低。平均随访时间为 66.1 个月(范围 60-71 个月)。VEGF165b/VEGF 比值越低,DR 进展的风险越大。
DR 患者房水中的 VEGF165b/VEGF 比值较低,VEGF165b/VEGF 比值降低预示着 DR 的进展。